Focused On-demand Library for Fc receptor-like protein 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

Fc receptor homolog 3; IFGP family protein 3; Immune receptor translocation-associated protein 3; MAIA; SH2 domain-containing phosphatase anchor protein 2

Alternative UPACC:

Q96P31; A0N0M4; A8MTH7; D3DVD2; Q5VXZ8; Q8N6S2; Q96LA4; Q96P27; Q96P28; Q96P29; Q96P30


Fc receptor-like protein 3, also known as Fc receptor homolog 3, plays a pivotal role in immune regulation. It promotes TLR9-induced B-cell proliferation and survival, while inhibiting antibody production. This protein also modulates NF-kappa-B and MAPK signaling pathways in B-cells, and has a unique role in sperm-egg adhesion and fusion during fertilization by interacting with the IZUMO1-IZUMO1R/JUNO sperm-egg complex.

Therapeutic significance:

Given its involvement in Rheumatoid arthritis, a disease with autoimmune features affecting the joints, Fc receptor-like protein 3 presents a promising target for therapeutic intervention. Understanding its regulatory mechanisms could lead to novel treatments for autoimmune diseases and fertility disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.